Fibromyalgia & musculoskeletal pain
Exploring the effects of GLP-1 receptor agonists in fibromyalgia: a propensity-matched real-world cohort using the TriNetX research platform
Authors' conclusion
GLP-1RA use was associated with reduced opioid prescription and a reduction in the use of ICD-10 codes related to fibromyalgia, potentially reflecting lower symptom burden.
Study context
- Population
- Patients with FM (≥2 diagnostic encounters), TriNetX Research Network, matched for age, sex and key comorbiditiespropensity-matched cohort
- Participants
- 48,025 vs 48,025
- Exposure
- GLP-1RA use vs no GLP-1RA use
- GLP-1RAn = 48,025
- Non-GLP-1RAn = 48,025reference
- Outcome
- Opioid use and symptom burden (diagnostic codes for pain, fatigue and disability), BMI and haemoglobin A1C
- Follow-up
- five-year follow-up
Methodological detailspropensity score matched 1:1, TriNetX Research Network, five-year follow-up
- Propensity score matched 1:1
- TriNetX Research Network
- Five-year follow-up
Main finding
As reported in the abstract
Odds ratio (opioid prescription)
0.65
P < 0.001
GLP-1RA
Odds ratio (pain diagnostic codes)
0.79
P < 0.001
GLP-1RA
Odds ratio (fatigue diagnostic codes)
0.68
P < 0.001
GLP-1RA
Observational data: associations, not effects.
Original publication
Exploring the effects of GLP-1 receptor agonists in fibromyalgia: a propensity-matched real-world cohort using the TriNetX research platform. Rheumatology (Oxford). Published 29 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →